Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions
PTSD
Interventions
DRUG

Glecaprevir/pibrentasvir

Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection

OTHER

Placebo

Compounded, inactive pill equal in appearance to active study drug

Trial Locations (1)

05001

RECRUITING

White River Junction VAMC, White River Junction

All Listed Sponsors
lead

White River Junction Veterans Affairs Medical Center

FED

NCT05637879 - Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder | Biotech Hunter | Biotech Hunter